Sara Graybill, MD
Family Medicine · Grand Island, NENPI 1932152907
Payments from drug & device makers
Across 135 payments — averaging $14.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$694
- Johnson & Johnson$292
- Novo Nordisk$143
- Lilly USA, LLC$127
- Otsuka America Pharmaceutical, Inc.$90
- Abbott$73
- plus $527 from 17 others
What the payments were for
- Food & beverage$1,947100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $694 |
| Johnson & Johnson | 13 | $292 |
| Novo Nordisk | 9 | $143 |
| Lilly USA, LLC | 8 | $127 |
| Otsuka America Pharmaceutical, Inc. | 5 | $90 |
| Abbott | 3 | $73 |
| AstraZeneca | 3 | $65 |
| Exact Sciences | 3 | $59 |
| Alydia Health | 3 | $56 |
| GSK | 4 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $34 |
| Pfizer | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 4 | $20 |
| Ardelyx, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Bayer | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Novartis | 1 | $12 |
How this compares
$1,947 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $90,303 |
| Humira PenAdalimumab | 13 | $89,649 |
| EliquisApixaban | 99 | $64,707 |
| FarxigaDapagliflozin Propanediol | 112 | $64,443 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $57,364 |
| MounjaroTirzepatide | 45 | $47,061 |
| TrulicityDulaglutide | 39 | $44,687 |
| JardianceEmpagliflozin | 66 | $38,011 |
| XareltoRivaroxaban | 29 | $30,879 |
| JanuviaSitagliptin Phosphate | 45 | $26,876 |
| LinzessLinaclotide | 42 | $21,921 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $19,004 |
| Nurtec OdtRimegepant Sulfate | 14 | $17,793 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $8,668 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 21 | $6,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $127 | $91,74884 claims |
| Novo NordiskOzempic | $143 | $90,30394 claims |
| PfizerEliquis, Nurtec Odt | $32 | $82,500113 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix | $56 | $75,431134 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $65 | $74,268135 claims |
| Johnson & JohnsonXarelto | $292 | $30,87929 claims |
| MerckJanuvia | $21 | $26,87645 claims |
| AbbVieLinzess | $694 | $21,92142 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $22 | $6,11013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Grand Island
- Adam BroszGrand Island$60M
- James OmelGrand Island$67K
- Brandon EssinkCreighton$92.8M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.